Glenmark Pharmaceuticals Limited (GLENMARK)
ISIN: - Industry: Drug Manufacturers—Specialty & Generic Sector: Healthcare Website
390.2
0.85(0.22%)

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISB 1302, a HER2 X CD3 beat bispecific antibody that is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.

Pricing Updates

TODAY'S HIGH

393.95

TODAY'S LOW

388.6

52 WEEK HIGH

690.95

52 WEEK LOW

348.5

Major Holders

% of Shares Held by
All Insider

52.07%

% of Shares Held by
Institutions

22.17%

% of Float Held by
Institutions

46.26%

Number of Institutions
Holding Shares

68

Company Overview

MARKET CAP

11014.52 Cr.

ETERPRISE VALUE

13664.58 Cr.

NO. OF SHARES

28.21 Cr.

BOOK VALUE

321.797

DIV. YIELD

2.5%

DEBT

3962.02 Cr.

GROSS PROFIT

8086.29 Cr.

CASH

1411.51 Cr.

REVENUE

12471.57 Cr.

REVENUE/SHARE

441.937

OHLC Chart 1y 2y 5y 10y

Price Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Volumes Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Cashflows

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Investments-10.01 Cr.-10.01 Cr.5 Cr.-15 Cr.
Change To Liabilities84.75 Cr.160.47 Cr.152.73 Cr.449.46 Cr.
Total cashflows from Investing Activities-333.28 Cr.-675.23 Cr.-783.51 Cr.-698.99 Cr.
Net Borrowings-1189.13 Cr.-77.71 Cr.-74.65 Cr.-369.29 Cr.
Total Cash from Financing Activities-520.49 Cr.-441.77 Cr.-444.66 Cr.-738.73 Cr.
Other Liabilities106.66 Cr.-294.59 Cr.169.75 Cr.71.14 Cr.
Total Assets0000
Net Income941.71 Cr.970.08 Cr.775.97 Cr.924.99 Cr.
Change in Cash272.43 Cr.27.82 Cr.173.99 Cr.-297.07 Cr.
Effect of Exchange Rate17.55 Cr.13.62 Cr.9.76 Cr.-183.52 Cr.
Total Cash from Operating Activities1108.65 Cr.1131.21 Cr.1392.41 Cr.1324.17 Cr.
Depreciation486.71 Cr.316.24 Cr.271.01 Cr.325.90 Cr.
Other Cashflows from Investing Activities465.27 Cr.8.90 Lakhs-13.17 Cr.-73.89 Cr.
Dividends Paid-92.69 Cr.-70.44 Cr.-68.55 Cr.-67.88 Cr.
Change to Inventory-203.41 Cr.-133.80 Cr.97.25 Cr.-428.70 Cr.
Change to Account Receivables-549.26 Cr.-117.90 Cr.-292.67 Cr.44.43 Cr.
Other Cashflows from Financing Activities761.34 Cr.-293.62 Cr.-301.45 Cr.-301.56 Cr.
Change to Net Income241.48 Cr.103.40 Cr.72.21 Cr.-63.06 Cr.
Capital Expenditures-790.11 Cr.-774.75 Cr.-931.37 Cr.-1237.17 Cr.

Financials

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Research DevelopmentNoneNoneNoneNone
Effect of Accounting ChargesNoneNoneNoneNone
Income Before Tax1441.24 Cr.1382.47 Cr.1096.07 Cr.1300.62 Cr.
Minority Interest351.47 Cr.-35.40 Lakhs-39.20 Lakhs-37.70 Lakhs
Net Income2000.25 Cr.1762.90 Cr.1298.38 Cr.1259.89 Cr.
Selling General Administrative2447.41 Cr.2810.25 Cr.2862.66 Cr.2873.77 Cr.
Gross Profit8086.29 Cr.7143.83 Cr.6808.53 Cr.6362.43 Cr.
Ebit2000.25 Cr.1762.90 Cr.1298.38 Cr.1259.89 Cr.
Operating Income2000.25 Cr.1762.90 Cr.1298.38 Cr.1259.89 Cr.
Other Operating Expenses3151.90 Cr.2127.12 Cr.2230.32 Cr.1902.85 Cr.
Interest Expense-298.09 Cr.-353.11 Cr.-377.31 Cr.-334.58 Cr.
Extraordinary ItemsNoneNoneNoneNone
Non RecurringNoneNoneNoneNone
Other ItemsNoneNoneNoneNone
Income Tax Expense447.59 Cr.412.38 Cr.320.10 Cr.375.63 Cr.
Total Revenue12471.57 Cr.10990.79 Cr.10657.26 Cr.9865.46 Cr.
Total Operating Expenses10471.31 Cr.9227.89 Cr.9358.88 Cr.8605.57 Cr.
Cost of Revenue4385.28 Cr.3846.96 Cr.3848.72 Cr.3503.03 Cr.
Total Other Income Expense Net-559.01 Cr.-380.42 Cr.-202.30 Cr.40.73 Cr.
Discontinued OperationsNoneNoneNoneNone
Net Income from Continuous Ops.993.64 Cr.970.08 Cr.775.97 Cr.924.99 Cr.
Net Income Applicable to Common Shares941.71 Cr.970.08 Cr.775.97 Cr.924.99 Cr.

Balance Sheet

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Intangible Assets2225.37 Cr.2276.93 Cr.2129.19 Cr.1682.27 Cr.
Capital Surplus01685.36 Cr.1685.36 Cr.1685.36 Cr.
Total Liabilities7645.16 Cr.8539.30 Cr.8614.69 Cr.7690.84 Cr.
Stock Holder Equity9086.64 Cr.7064.62 Cr.6070.50 Cr.5605.18 Cr.
Minority Interest351.47 Cr.-35.40 Lakhs-39.20 Lakhs-37.70 Lakhs
Other Liabilities1210.48 Cr.455.77 Cr.480.04 Cr.404.91 Cr.
Total Assets17083.28 Cr.15603.57 Cr.14684.80 Cr.13295.64 Cr.
Common Stock28.21 Cr.28.21 Cr.28.21 Cr.28.21 Cr.
Retained Earnings07379.13 Cr.6475.19 Cr.5760.47 Cr.
Other Liabilities183.99 Cr.225.43 Cr.214.37 Cr.95.99 Cr.
Good Will60.01 Cr.58.01 Cr.52.89 Cr.54.73 Cr.
Treasury Stock9058.43 Cr.-2028.08 Cr.-2118.26 Cr.-1868.87 Cr.
Other Assets1854.19 Cr.1681.58 Cr.1580.01 Cr.1484.75 Cr.
Cash1411.51 Cr.1138.09 Cr.1110.27 Cr.936.27 Cr.
Current Liabilities4689.43 Cr.4201.02 Cr.4125.98 Cr.4021.09 Cr.
Long Term Asset Charges1686.12 Cr.1534.66 Cr.1455.70 Cr.1389.80 Cr.
Short Long Term Debt1098.60 Cr.285.59 Cr.383.04 Cr.571.89 Cr.
Other Stockholder Equity9058.43 Cr.-2028.08 Cr.-2118.26 Cr.-1868.87 Cr.
Property Plant Equipment4611.71 Cr.4175.57 Cr.4068.34 Cr.3332.18 Cr.
Total Cur. Assets8282.34 Cr.7359.57 Cr.6803.61 Cr.6696.82 Cr.
Long Term Investments49.62 Cr.51.89 Cr.50.73 Cr.44.87 Cr.
Net Tangible Assets6801.24 Cr.4729.67 Cr.3888.40 Cr.3868.17 Cr.
Short Term Investments09.34 Cr.8.18 Cr.68.88 Cr.
Net Receivables3101.13 Cr.3051.74 Cr.2866.56 Cr.2827.91 Cr.
Long Term Debt2571.74 Cr.3888.81 Cr.4042.99 Cr.3573.75 Cr.
Inventory2499.83 Cr.2276.83 Cr.2135.62 Cr.2252.07 Cr.
Accounts Payable2288.66 Cr.2237.76 Cr.2125.84 Cr.2220.75 Cr.

New Offers


Upstox offer
Upstox

Open a demat account through us and get the account opening charges waived off

open paperless account